This year, we expect to achieve our export target of $8 million.
"The goal is to become the number one health and wellness company in Asia."
DxVx has officially begun exporting its own microbiome-branded products overseas, driving the company's performance growth.
DxVx announced on the 25th that it recently signed export contracts with the EU for its microbiome-based health supplements, including "Formulamate-Ofmom," totaling $2.2 million (approximately 3 billion Korean won). The company is currently negotiating export arrangements with new partners in China, Japan, Southeast Asia, and the Middle East.
It's worth noting that the subsidiary's biopharmaceutical plant in South Korea has completed the Food Facility Registration (FFR) process with the U.S. Food and Drug Administration. With the company's continued expansion into overseas markets, exports are expected to experience rapid growth. DxVx won the '$3 Million Export Tower Award' at last year's Trade Day, and its export volume has now more than doubled; it is expected to win the award again this year.
DxVx is currently opening flagship stores for its DxVx and Ofmom brands on online platforms in major overseas countries. It is expected that by the end of this year, these flagship stores will be available on global online shopping platforms such as Amazon.com in the US, Rakuten and Amazon Japan in Japan, Tmall and TikTok in China, and Shopee and Lazada in Southeast Asia. Simultaneously, the company will directly sell its Ofmom nutrition brand products and 12 DxVx products developed and manufactured by the COREE Italian Research Institute, which will be launched in November, to global consumers via a B2C model, enabling direct overseas purchases.
DxVx possesses a complete industry chain encompassing research, development, production, and distribution, enabling it to rapidly develop relevant products based on healthcare market trends in various countries. Furthermore, the company stated that it is currently building a global online and offline professional marketing department and network, giving it a competitive edge in expanding its global market presence.
Furthermore, DxVx, centered around its own Microbiome Research Institute, collaborates with the Italian AAT Research Institute of the Koly Group to develop new microbiome-based drugs, customized healthcare products, and novel materials. Recently, DxVx officially entered the Chinese maternal and infant healthcare market by launching essential antibiotics through its Chinese subsidiary. Currently, it is further expanding the quantity and sales volume of its subsequent essential and best-in-class pharmaceutical products. The first-phase goal is to become the leading healthcare company in Asia, providing customized healthcare solutions based on the microbiome, including prevention and treatment, through diagnostics.
A DxVx representative stated, "Following the COVID-19 pandemic, global consumer spending on immune health supplements has increased, and there has been a rise in favorability towards Korean health supplements. Considering our current global marketing network, we expect to successfully achieve our export target of $8 million this year." The representative added, "We will set even more challenging overseas market sales targets for 2024, hoping to achieve a leap in growth."
